Is enzalutamide/enzalutamide (Encotan) a targeted drug?

Enzalutamide/Whether Enzalutamide is a targeted drug is a question often raised by patients when understanding the mechanism of medication. Strictly speaking, enzalutamide is a new androgen receptor inhibitor that binds to and blocks the androgen receptor, thereby cutting off the signaling pathways that prostate cancer cells rely on. Although it does not belong to the "molecular targeted drugs" in the traditional sense, such as tyrosine kinase inhibitors targeting specific gene mutations, in terms of its mechanism of action, it also embodies the core concept of targeted therapy, which is to control disease development through selective intervention of key molecules.

Within the broad classification of oncology, targeted drugs refer to therapeutic drugs that act on specific molecular targets. Enzalutamide is designed to target the core target of the androgen receptor, so many experts also classify it as part of targeted therapy. Compared with chemotherapy drugs, it does not kill all rapidly proliferating cells indiscriminately, but focuses on signaling pathways closely related to tumor occurrence and development, so the side effects are relatively more controllable and the efficacy is more precise. This is also an important reason why enzalutamide can be included in global prostate cancer treatment guidelines.

Data show that enzalutamide not only prevents androgens from binding to receptors, but also inhibits receptor translocation and gene transcription. It is a multi-level target intervention method. This characteristic makes it similar to small molecule targeted drugs, but it works on different targets. For patients, the most important thing is its clinical effect rather than strict classification.

From a practical application perspective, enzalutamide targets androgen receptors as its main mechanism, embodying the advantages of targeted drugs in the treatment process and having the feasibility of long-term use. In summary, although enzalutamide is mostly referred to as a "new androgen receptor inhibitor" in academic classifications, from the perspective of therapeutic principles and applications, it can be understood as a type of targeted drug. Especially in the management of prostate cancer, it has become an important representative of targeted therapy.

Reference materials:https://www.xtandi.com/